NCT00937768View on ClinicalTrials.gov

Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

June 30, 2012

Study Completion Date

July 31, 2012

Conditions
Prostate AdenocarcinomaStage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

Goserelin Acetate

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Leuprolide Acetate

Given IM

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT00937768 - Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | Biotech Hunter | Biotech Hunter